GABA Composition for Early Cognitive Decline Intervention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a composition that can suppress the reduction in cognitive function or improve cognitive function, particularly in elderly individuals, as mild cognitive impairment and dementia are prevalent and progressive conditions with limited cure options, necessitating early intervention to delay symptom progression.
Innovation Solution
A composition comprising γ-aminobutyric acid (GABA) is developed to enhance cognitive functions such as reasoning, working memory, sustained attention, spatial cognition, and memory, measured by Cognitrax and RBANS neuropsychological tests, and improve physical function, vitality, and mental health, potentially through increasing insulin-like growth factor-1 (IGF-1) concentration in blood.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If early intervention is implemented to delay dementia progression, then cognitive function deterioration is suppressed, but complete cure remains impossible due to the progressive nature of dementia
Solution Approach 1:
The patent applies preliminary action by administering GABA before cognitive function significantly deteriorates. The composition is designed for early intervention in subjects with mild cognitive impairment or those at risk, aiming to prevent or delay the progression to full dementia rather than treating advanced stages. This proactive approach aligns with the principle of performing required action in advance to prevent harmful outcomes.
2Reliability
If GABA composition is administered to improve cognitive function, then reasoning, working memory, and attention are enhanced, but the mechanism through IGF-1 concentration increase is not fully understood
Solution Approach 1:
The patent incorporates feedback mechanisms by measuring IGF-1 concentration in blood as an indicator of GABA composition effectiveness. The patent specifies that the composition should increase IGF-1 concentration, using this biomarker as feedback to verify the mechanism of action. This allows for monitoring and validation of the proposed mechanism while continuing research into the full understanding of GABA's cognitive enhancement pathways.
3Reliability
If GABA content is increased to enhance cognitive effects, then cognitive function improvement is enhanced, but optimal dosage range must be determined to avoid potential side effects
Solution Approach 1:
The patent applies parameter changes by specifying an optimal GABA content range of 10-1000 mg per composition unit and an ingestion amount of 10-1000 mg per day. This quantitative parameter optimization balances effectiveness in improving cognitive function with safety considerations. The patent identifies this specific dosage range as optimal for increasing IGF-1 concentration and enhancing cognitive performance while minimizing potential adverse effects.
Data Source
AI summary
A composition for preventing the deterioration in a cognitive function or improving the cognitive function in a subject. A composition for preventing the deterioration in a cognitive function and/or improving the cognitive function in a subject, the composition containing γ-aminobutyric acid.